Tonix Pharmaceuticals to Participate in Two Investor Conferences in May

About this update from Tonix Pharmaceuticals Holding Corp.

[{"type":"image","alt":"Tonix Pharmaceuticals Holding Corp.","displaySize":"","headline":null,"caption":"Tonix Pharmaceuticals Holding Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EdKFmNH98aOvPDYgJOIgkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Ng--/https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d","width":300,"height":140},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EdKFmNH98aOvPDYgJOIgkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Ng--/https://media.zenfs.com/en/globenewswire.com/7794549bf2784a219c2135212e93833d","width":300,"height":140}},"lazy":false},{"type":"text","content":"BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in May 2026.","length":317,"tagName":"p"},{"type":"text","content":"RBC Capital Markets Global Healthcare ConferenceFireside ChatParticipant: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: New York, New YorkDate: May 19, 2026Time: 1:35 p.m. ET","length":226,"tagName":"p"},{"type":"text","content":"A.G.P.’s Annual Virtual Healthcare ConferenceFireside ChatPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsLocation: VirtualDate: May 20, 2026Time: 3:00 p.m. ET","length":210,"tagName":"p"},{"type":"text","content":"Live webcasts and replays will be available under the News & Events tab in the Investors section of the Tonix website at https://ir.tonixpharma.com/.","length":153,"tagName":"p"},{"type":"text","content":"Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembra...

More updates from Tonix Pharmaceuticals Holding Corp.